News Classic

STAFFORD, Texas, Oct. 17, 2024 (GLOBE NEWSWIRE) — According to a new survey conducted by The Harris Poll on behalf of Money Management International (MMI), over four in five Americans with credit card debt (83%) report having struggled to make ends meet this year, with inflation likely a primary factor. With the rising cost of living, MMI has seen a significant increase in the number of people seeking financial counseling and help with managing credit card debt.

The survey highlights that nearly three in four Americans with credit card debt (73%) point to inflation as one of the most significant pressures on their household budget. The cost of essential items like groceries and utilities has compounded financial stress for many households. New clients seeking financial counseling from MMI report an average household budget deficit of nearly $300 per month, a shortfall that has doubled in the last two years.  

Real-Life Struggles

In our survey, those with credit card debt who made changes to finances to make ends meet shared some of their challenges. A 71-year-old male shared that one of the most difficult changes they’ve had to make is “trying to find the cheapest foods to prepare, especially meat proteins. I can’t afford beef at all anymore, and I’m only buying the cheapest chicken and pork…I buy canned and frozen fruits and vegetables because they are cheaper than fresh.” Similarly, a 46-year-old female shared that one of the most difficult changes they’ve had to make is, “delaying a vacation and a new car purchase due to discretionary income reduction.”

Surge in Credit Counseling

MMI’s proprietary data reflects the growing financial stress among consumers. Through Q3 2024, MMI has experienced a 42% increase in new clients overall, with a 9% increase in the total unsecured debt they carry, compared to the first three quarters of 2023.

“Americans are clearly feeling the pinch of rising costs,” said Thomas Nitzsche, Sr. Director of Media & Brand at MMI. “More people are turning to us for help as they try to keep up with everyday necessities like groceries and utility bills. We’re seeing firsthand how inflation is driving people to cut back on non-essential spending and seek out debt management solutions.”

Demographic Insights: A Broadening Crisis

MMI’s data reveals significant demographic shifts in those seeking assistance in 2024. Among the key findings:

• More younger Americans have sought out credit counseling, with disproportionate increases among those under 35 years of age.
• Hispanic Americans seeking credit counseling grew by 66%, while non-Hispanic clients increased by 40%.
• African Americans seeking help grew by 31%, while Asian Americans saw a 50% increase.
• The states of Arizona, Minnesota, New York, Oklahoma, and Texas have seen above-average increases in both counseling volume and unsecured debt loads.
• Puerto Rico has experienced a notable 125% surge in demand for credit counseling.

Changing Financial Habits

As Americans adjust to new financial realities, many are making difficult choices. Among those with credit card debt who have struggled financially, MMI’s survey with The Harris Poll found that more than nine in ten (92%) have made changes to their spending habits. The most common adjustment is reduced spending on dining out and/or entertainment (54%). Other shifts include cutting back on vacations or travel (48%), postponing major purchases (40%), and increasing use of credit cards (38%). Nearly one in three (30%) have reduced their savings or retirement contributions. 

Survey Methodology

This survey was conducted online within the United States by The Harris Poll on behalf of MMI from October 3-7, 2024 among 2,085 U.S. adults ages 18 and older, among whom 1,049 have credit card debt. The sampling precision of Harris online polls is measured by using a Bayesian credible interval.  For this study, the sample data is accurate to within +/- 2.5 percentage points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact Thomas.Nitzsche@MoneyManagement.org.  

About MMI

Money Management International (MMI) has been at the forefront of financial health solutions for over 65 years. As a leading nonprofit organization, MMI is dedicated to changing how America overcomes financial challenges by offering timely and expert guidance. Recognized by major financial organizations and media outlets, MMI’s programs help individuals reach their financial goals and foster a life of financial wellness. Learn more at MoneyManagement.org.

For reporters looking to interview real people for stories, MMI has created a group of nearly 500 clients from across the country who are willing to share their experiences with the media in the hopes of helping others challenged with debt. These peer advocates have paid off over $19 million of debt and now serve as MMI ambassadors. Hear from them on MMI’s podcast, Long Story $hort. 

To schedule an interview with an MMI expert or debt management client, please contact:

Thomas Nitzsche, 404.490.2227, Thomas.Nitzsche@MoneyManagement.org  

Lori Geary, 404.551.2151, lgeary@lexiconstrategies.com 

Thomas Nitzsche
Money Management International
404.490.2227
Thomas.Nitzsche@MoneyManagement.org

Lori Geary
Lexicon Strategies
404.551.2151
lgeary@lexiconstrategies.com

Wilmington, Delaware, United States, Transparency Market Research, Inc., Oct. 17, 2024 (GLOBE NEWSWIRE) — The pharmerging market accounted for US$ 2.1 billion in 2023. It is expected to advance at a CAGR of 11.6% from 2024 to 2034 and reach US$ 7.1 billion by the end of 2034. Pharmaceuticals are in higher demand to manage and treat chronic diseases, including diabetes, cardiovascular disease, and cancer, as they become more prevalent in emerging economies.

The pharmaceutical industry’s healthcare infrastructure is receiving more funding from governments and the private sector in emerging nations to facilitate better access and quality to healthcare. Pharmerging markets frequently encounter issues with healthcare access and drug affordability. Innovative pricing strategies, biosimilar, and generic medications could reduce healthcare costs in the future.

Telemedicine and digital health solutions may change how healthcare is delivered in emerging nations as smartphone and internet access expands. Remote consultations can be facilitated, healthcare access can be improved, and chronic illness monitoring can be simplified through these innovations.

Request a PDF Sample of this Report Now!
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8200

Building hospitals, clinics, and diagnostic centers is essential to improving healthcare access and provision worldwide. Among the creative ways to develop infrastructure, modular and prefabricated construction techniques could hasten the development of healthcare facilities worldwide.

Developing economies are going through a transition in terms of disease patterns as their economies develop. Pharmaceutical research and development activities are proving to be a driving force in the growth of various regional markets in the pharmaceutical industries.

Key Players Profiled

• Abbott Laboratories
• Koninklijke Philips N.V.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca
• GlaxoSmithKline plc
• Lupin
• Tata Consultancy Services Ltd.
• Sun Pharmaceutical Industries Ltd.
• Huadong Medicine Co. Ltd.

Key Findings of the Market Report

• Based on product type, the pharmaceuticals segment is likely to drive demand for pharmerging market.
• In terms of indication, cancer and autoimmune diseases are expected to drive pharmerging market growth.
• The hospitals segment generated a major share of revenue in 2023.
• In 2023, the Asia-Pacific region held the majority of the market share.

Global Pharmerging Market: Growth Drivers

• The regulatory environment of pharmaceutical businesses is constantly changing, which impacts their strategies and operations as well as the prices, reimbursement policies, and entry into the market. Healthcare infrastructure advancements such as increased accessibility to healthcare facilities and distribution networks, make pharmacies more accessible in emerging markets.
• Innovations in biotechnology and personalized medicine are propelling pharmaceutical research and development. This results in novel treatments and therapies being introduced. Biotechnology advancements are propelling the creation of customized medications based on the genetic composition and disease attributes of particular patients.
• Pharmaceutical markets may be able to make use of these advancements to lower medical expenses and enhance treatment results. Drug delivery innovations, like implantable devices and systems based on nanotechnology, have the potential to improve patient adherence to treatment plans and increase medication safety and efficacy.
• Pharmaceutical companies have benefited from health insurance plans and universal healthcare coverage, increasing patient access to pharmaceuticals and improving healthcare quality. Growing patient empowerment and health knowledge encourage people to seek medical treatment and prescription drugs, propelling the growth of the pharmaceutical industry in emerging markets.

Global Pharmerging Market: Regional Landscape

• Asia Pacific is expected to lead the pharmerging market. With countries like China and India having large populations, the Asia-Pacific area is home to a sizable share of the global population. Numerous governments in the area are investing in healthcare infrastructure, including broadening the reach of healthcare facilities, implementing universal health coverage, and improving regulatory frameworks to facilitate pharmaceutical growth.
• The need for pharmaceuticals for prevention, treatment, and management is driven by changes in disease patterns, such as an increase in the prevalence of non-communicable diseases (NCDs) like diabetes, cardiovascular disease, and cancer. Healthcare reforms drive pharmaceutical market expansion to enhance healthcare quality, cost, and access. Intellectual property rights, pricing and reimbursement practices, and regulatory harmonization are a few examples of these reforms.
• Healthcare technology, including telemedicine, digital health solutions, and genomics, is advancing quickly in Asia-Pacific. Pharmaceutics research, development, and market expansion are fueled by these developments, especially in the biotechnology and specialty medication sectors.

Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8200

Global Pharmerging Market: Competitive Landscape
Pharma and healthcare companies can form strategic partnerships with other companies, research institutions, and healthcare providers to drive innovation, expand market reach, and improve drug discovery, development, and delivery capabilities.

Key Developments

• Abbott Laboratories is a leading product manufacturer of medical devices, generic pharmaceuticals, diagnostics, nutritional products, and branded pharmaceuticals.
• Koninklijke Philips N.V. is an international company that specializes in healthcare, lighting, and consumer products. Aside from healthcare equipment, they offer a variety of services.
• F. Hoffmann-La Roche Ltd. is one of the world’s leading pharmaceutical and diagnostic companies. Innovative treatments are offered in fields such as immunology, oncology, infectious diseases, and others.

Global Pharmerging Market: Segmentation
Product Type

• Branded Prescription Drugs
• Generic Drugs

• Branded Generics
• Unbranded Generics
• Healthcare

• Medical Devices
• Diagnostic Instruments
• Others (IT and Record Management)

Indication

• Lifestyle Diseases
• Cancer and Autoimmune Diseases
• Infectious Diseases
• Others

Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• E-commerce
• Drugs Stores

Region

• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=8200&ltype=S

More Trending Reports by Transparency Market Research –

• Vaccines Market– The global vaccines market is projected to advance at a CAGR of 4.2% from 2023 to 2031.
• Diabetes Devices Market – The global diabetes devices market is projected to expand at a CAGR of 6.0% during the forecast period from 2022 to 2031.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com    
Email: sales@transparencymarketresearch.com

Follow Us: LinkedIn| Twitter| Blog | YouTube

Source: Michael Ballanger 10/15/2024

Michael Ballanger of GGM Advisory Inc. sends his thoughts on the current state of the market, looking at oil, copper, gold, and silver.

The USD Index futures are down 0.167% to 102.915 this morning with the 10-yr. (-1.39%) yield down to 4.068% and 30-yr. (-0.27%) down at 4.37%.

The metals are mixed with gold (+0.27%) and silver (+0.43%) higher, but copper (-1.11%) is down to $4.35/lb. Oil (-3.74%) is sharply lower, trading at USD $70.88/bbl. Stock futures are higher, with the DJIA futures up .04% and the S&P 500 futures (+0.04%) up, while NASDAQ futures are up by 0.04%. Risk barometer Bitcoin is up $702 to $65,704(+ 1.08%).

Due largely to the “Seasonal MACD Buy Signal” issued by The Stocks Trader’s Almanac yesterday, the Best Six Months of the trading year have just kicked into gear, with the major averages at or near all-time highs. The DJIA hit an all-time high yesterday at 43,139, with the S&P 500 hitting its ATH last Friday.

The NASDAQ Composite hit an ATH on July 11 at 18,671 and remains 169 points away. The Russell 2000 (small cap index) hit its ATH back in October 2021, with the ETF trading at $230.72 and is now $7.83 points away. Considering that September and October are seasonally weak months, it has been a statistical anomaly to be registering ATHs in mid-October during a presidential election year, but then again, this entire market is a “statistical anomaly” in many respects as I indicated last evening with those four charts. There was a time when one could use historical market patterns to time entries and exits, but with the algobots now controlling well over 70% of the volume on the NYSE, these historical norms are becoming less relevant every year.

Nonetheless, the markets are quickly approaching overbought territory and as can be observed from the chart of the S&P, it is trading a full 11.1% above its 200-dma, which is “overextended”, to put it mildly. I have to respect seasonality, so if there has been no meaningful drawdown by the end of this week, I will be looking to add a few calls in anticipation of a year-end rally.

Copper

I am posting the copper chart this morning and drawing your attention to the 100-DMA at $4.36/lb. With the price now beneath that level at $4.35 along with the overnight low of $4.3317, a close below the 100-dma sets up a test of the convergence zone between the 50- dma @ $4.27 and the 200-dma @ $4.24. That should be enough to take Freeport-McMoRan Inc. FCX back below the gap it created after the Chinese stimulus package was announced that took the stock from $45 on the close the prior session only to open $3.00 higher the following day at $48.10.

I was uneasy about selling the FCX calls and half of the shares back in the $51.50 range a few weeks back, but sometimes the discipline one acquires after being beaten like a common farm animal so many times pays off. I cannot count the number of times I stayed in a position that moved from a win to a loss because I failed to heed the old adage, “When conditions change, one must change.” When copper went into overbought conditions in late September, conditions changed. Hopefully, they are about to change again for the better.

Important Disclosures:

1. Michael Ballanger: I, or members of my immediate household or family, own securities of: Freeport-McMoRan Inc. I determined which companies would be included in this article based on my research and understanding of the sector.
2. Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
4. Michael Ballanger Disclosures

This letter makes no guarantee or warranty on the accuracy or completeness of the data provided. Nothing contained herein is intended or shall be deemed to be investment advice, implied or otherwise. This letter represents my views and replicates trades that I am making but nothing more than that. Always consult your registered advisor to assist you with your investments. I accept no liability for any loss arising from the use of the data contained on this letter. Options and junior mining stocks contain a high level of risk that may result in the loss of part or all invested capital and therefore are suitable for experienced and professional investors and traders only. One should be familiar with the risks involved in junior mining and options trading and we recommend consulting a financial adviser if you feel you do not understand the risks involved.

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk NVO.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don’t know. But when something this big happens with NVO, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga‘s options scanner spotted 15 uncommon options trades for Novo Nordisk.

This isn’t normal.

The overall sentiment of these big-money traders is split between 53% bullish and 40%, bearish.

Out of all of the special options we uncovered, 4 are puts, for a total amount of $369,668, and 11 are calls, for a total amount of $1,968,285.

Expected Price Movements

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $130.0 for Novo Nordisk over the last 3 months.

Analyzing Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk’s options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk’s substantial trades, within a strike price spectrum from $90.0 to $130.0 over the preceding 30 days.

Novo Nordisk Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

In light of the recent options history for Novo Nordisk, it’s now appropriate to focus on the company itself. We aim to explore its current performance.

Present Market Standing of Novo Nordisk

• With a trading volume of 1,633,351, the price of NVO is up by 0.47%, reaching $118.59.
• Current RSI values indicate that the stock is may be oversold.
• Next earnings report is scheduled for 20 days from now.

What Analysts Are Saying About Novo Nordisk

A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $158.66666666666666.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160.
* Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Novo Nordisk with a target price of $156.
* Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.